Abstract:MicroRNAs (miRNAs) are small, non-coding regulatory RNAs that post-transcriptionally regulate gene expression. These conserved molecules are highly expressed in the brain, being essential for neuronal function and survival. miRNA profiles are significantly altered in Alzheimer's disease (AD) patient brains. We have previously shown that tauroursodeoxycholic acid (TUDCA) is a strong neuroprotective agent in several AD experimental models. In addition, bile acids modulate both mRNA and miRNA expression in the rat liver. Nevertheless, the therapeutic role of TUDCA in AD pathology has not yet been ascertained. The present study was designed to identify miRNAs differentially expressed in wild-type and APP/PS1 transgenic mice, as well as elucidate the role of TUDCA in modulating miRNAs potentially associated with AD. We carried out highly sensitive expression profiling of 1140 miRNAs on samples obtained from the hippocampus and frontal cortex of male APP/PS1 transgenic mice and wild-type littermates fed diets containing 0.4 percent TUDCA, or no bile acid, for 6 months. Validation was performed by qRT-PCR. APP/PS1 mice brains showed significant and large fold-change differential expression of 46 miRNAs including miR-295, -302c, -599, and -615, relative to wild-type mice. In addition, significant differences were also detected in 28 miRNAs in the direct comparison of untreated and TUDCA-treated APP/PS1 mice. Finally, in silico analysis identified putative target genes for specific miRNAs deregulated in APP/PS1 mice and modulated by TUDCA. Pathway enrichment within these putative targets revealed that miRNAs found altered in APP/PS1 mice are potentially involved in axon guidance mechanisms, long-term potentiation and/or depression, glutamate metabolism, and apoptosis. Interestingly, amyloid precursor protein (APP) 3'UTR is potentially targeted by miR-295, which expression was significantly decreased in the cortex of APP/PS1 mice. In contrast, miR-599 was upregulated in the brain of APP/PS1 mice and potentially targets the low-density lipoprotein (LDL) receptor-related protein 6 (LRP6) 3'UTR involved in Aβ clearance. Notably, miR-599 expression was decreased by TUDCA. miRNA profiling of APP/PS1 mice provides an appealing approach to address how changes in miRNA profiles translate into biological functions in AD pathological context. Modulation of AD-associated miRNAs by TUDCA may represent a potential therapeutic strategy for prevention and treatment of the disease.

Deletion of miR‐33, a regulator of the ABCA1–APOE pathway, ameliorates neuropathological phenotypes in APP/PS1 mice

Down‐regulated Expression of Microrna‐338‐5p Contributes to Neuropathology in Alzheimer's Disease

Genome-wide Analysis of Mirna Signature in the APPswe/PS1ΔE9 Mouse Model of Alzheimer's Disease.

MicroRNA-338-5p Alleviates Neuronal Apoptosis Via Directly Targeting BCL2L11 in APP/PS1 Mice

Mir-124 Downregulates Bace 1 and Alters Autophagy in App/Ps1 Transgenic Mice

Deletion of Abi3 gene locus exacerbates neuropathological features of Alzheimer’s disease in a mouse model of Aβ amyloidosis

The Microrna-1908 Up-Regulation in the Peripheral Blood Cells Impairs Amyloid Clearance by Targeting ApoE

miR-30a-5p induces Aβ production via inhibiting the nonamyloidogenic pathway in Alzheimer’s disease

MicroRNA-339-5p down-regulates protein expression of β-site amyloid precursor protein-cleaving enzyme 1 (BACE1) in human primary brain cultures and is reduced in brain tissue specimens of Alzheimer disease subjects

Loss of miR-369 Promotes Tau Phosphorylation by Targeting the Fyn and Serine/Threonine-Protein Kinase 2 Signaling Pathways in Alzheimer’s Disease Mice

MiR-191-5p alleviates microglial cell injury by targeting Map3k12 (mitogen-activated protein kinase kinase kinase 12) to inhibit the MAPK (mitogen-activated protein kinase) signaling pathway in Alzheimer’s disease

P3‐046: Understanding Brain Microrna Profiling in the Double Transgenic APP/PS1 Mouse Model of Alzheimer's Disease

miR-429-3p mediates memory decline by targeting MKP-1 to reduce surface GluA1-containing AMPA receptors in a mouse model of Alzheimer's disease

microRNA‐425 loss mediates amyloid plaque microenvironment heterogeneity and promotes neurodegenerative pathologies

O3‐01‐05: MIR‐204 ATTENUATES MEMORY DEFICITS IN A MOUSE MODEL OF ALZHEIMER'S DISEASE

Human microRNA (miR-20b-5p) modulates Alzheimer’s disease pathways and neuronal function, and a specific polymorphism close to the MIR20B gene influences Alzheimer’s biomarkers

Microglia prevent beta-amyloid plaque formation in the early stage of an Alzheimer’s disease mouse model with suppression of glymphatic clearance

Human microRNA-153-3p targets specific neuronal genes and is associated with the risk of Alzheimer's disease.

Folic Acid Deficiency Enhances Abeta Accumulation in APP/PS1 Mice Brain and Decreases Amyloid-Associated Mirnas Expression

miR-146a-5p Modulates Adult Hippocampal Neurogenesis Deficits Through Klf4/p-Stat3 Signaling in APP/PS1 Mice

MicroRNA‐128 Suppresses Tau Phosphorylation and Reduces Amyloid‐beta Accumulation by Inhibiting the Expression of GSK3β, APPBP2, and Mtor in Alzheimer's Disease